Biocryst Pharmaceuticals

1. BCX17725 Ph1 readoutby year-end 2026BCX17725 Ph1 readout, by year-end 2026, notable
2. deucrictibant Pharvaris NDA filing1H 2027deucrictibant Pharvaris NDA filing, 1H 2027, material
3. lonvo-z Intellia PDUFA dateMar 10, 2027lonvo-z Intellia PDUFA date, Mar 10, 2027, major
4. deucrictibant Pharvaris PDUFA dateApr 23, 2027deucrictibant Pharvaris PDUFA date, Apr 23, 2027, major
5. navenibart topline3Q 2027navenibart topline, 3Q 2027, thesis-defining
6. ORLADEYO corporate updateJul 2027ORLADEYO corporate update, Jul 2027, notable
7. navenibart filingby year-end 2027navenibart filing, by year-end 2027, material
8. ORLADEYO ANDA corporate updateDec 6, 2027ORLADEYO ANDA corporate update, Dec 6, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.